喘息治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Asthma - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0644
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:756
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥265,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥530,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD7,500 ⇒換算¥795,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Asthma – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Asthma – Pipeline Review, H2 2019, provides an overview of the Asthma (Respiratory) pipeline landscape.

Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Asthma – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Asthma (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Asthma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 15, 47, 32, 2, 111, 27 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 29 and 8 molecules, respectively.

Asthma (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Asthma (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Asthma (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Asthma (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Asthma (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Asthma (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Asthma (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Asthma (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Asthma – Overview
Asthma – Therapeutics Development
Asthma – Therapeutics Assessment
Asthma – Companies Involved in Therapeutics Development
Asthma – Drug Profiles
Asthma – Dormant Projects
Asthma – Discontinued Products
Asthma – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Asthma, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Products under Development by Companies, H2 2019 (Contd..13), H2 2019
Products under Development by Companies, H2 2019 (Contd..14), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Asthma - Pipeline by 2A Pharma AB, H2 2019
Asthma - Pipeline by 4D Pharma Plc, H2 2019

【掲載企業】

2A Pharma AB
4D Pharma Plc
AB Science SA
AbbVie Inc
Abeome Corp
Adamis Pharmaceuticals Corp
Adare Pharmaceuticals Inc
Advagene Biopharma Co Ltd
Aerami Therapeutics
Akeso Biopharma Inc
Algomedix Inc
ALK-Abello AS
Allergan Plc
Amgen Inc
Amphastar Pharmaceuticals Inc
AnaptysBio Inc
AnGes Inc
Antisense Therapeutics Ltd
Apollo Endosurgery Inc
Apollo Therapeutics LLC
Aquilon Pharmaceuticals SA
Argenx SE
Artax Biopharma Inc
Artizan Biosciences Inc
ASIT Biotech SA
Aslan Pharmaceuticals Ltd
AstraZeneca Plc
Atrapos Therapeutics LLC
Aurigene Discovery Technologies Ltd
Avidin Ltd
Bai Shuo Beijing Pharmaceutical Technology Co Ltd
Biocon Ltd
BiOraliX BV
BiosanaPharma BV
Biotec Pharmacon ASA
Boehringer Ingelheim International GmbH
Celltrion Inc
Celon Pharma SA
Chiesi Farmaceutici SpA
Chronic Airway Therapeutics Ltd
ConMed Biosciences Inc
Crossject SA
CrystalGenomics Inc
CSL Ltd
CSPC Pharmaceutical Group Ltd
Cumberland Pharmaceuticals Inc
Cynata Therapeutics Ltd
Cytokinetics Inc
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Denceptor Therapeutics Ltd
Dnarx LLC
EffectorBio Inc
Eleusis Ltd
EmphyCorp Inc
Energenesis Biomedical Co Ltd
Enterprise Therapeutics Ltd
Enzychem Lifesciences Corp
ethris GmbH
EURRUS Biotech GmbH
Exotect LLC
F. Hoffmann-La Roche Ltd
Fibrotherapeutics Inc
Foresee Pharmaceuticals Co Ltd
Fountain Biopharma Inc
GeneFrontier Corp
Genentech Inc
Generium
GeneScience Pharmaceuticals Co Ltd
GlaxoSmithKline Plc
GlycoMira Therapeutics Inc
Gossamer Bio Inc
Harbour BioMed
HEC Pharm Co Ltd
Hovione FarmaCiencia SA
Humanigen Inc
iCeutica Inc
Icure Pharmaceutical Inc
IGE Therapeutics Inc
ILiAD Biotechnologies LLC
Immune Regulation Ltd
Inatherys
InKemia IUCT Group SA
Innovimmune Biotherapeutics Inc
Inspyr Therapeutics Inc
Intech Biopharm Ltd
Invion Ltd
Irex Pharma LLC
JHL Biotech Inc
JiangSu Qyuns Therapeutics Co Ltd
Kashiv BioSciences LLC
KBP BioSciences Co Ltd
Kissei Pharmaceutical Co Ltd
Kither Biotech Srl
KLUS Pharma Inc
Knopp Biosciences LLC
KoBioLabs Inc
Kyowa Kirin Co Ltd
Laboratorios LETI SL
Lead Discovery Center GmbH
LG Chem Ltd
Lignamed LLC
Longevity Biotech Inc
Mabtech Ltd
Mariposa Health Ltd
Medicenna Therapeutics Corp
Mercia Pharma Inc
Merck & Co Inc
Mitsubishi Tanabe Pharma Corp
Mycenax Biotech Inc
NAL Pharmaceuticals Ltd
NeoPharm Co Ltd
Neovacs SA
Novartis AG
OliX Pharmaceuticals Inc
Omeros Corp
OncoArendi Therapeutics SA
Oncostellae SL
Ono Pharmaceutical Co Ltd
OPKO Health Inc
Opsidio LLC
Orbis Biosciences Inc
Orchid Pharma Ltd
Oxagen Ltd
Palo BioFarma SL
Pantherics Inc
Paradigm Biopharmaceuticals Ltd
Paragen Bio Pty Ltd
Pfizer Inc
PharmAbcine Inc
PharmaKing Co Ltd
Pharmaxis Ltd
Pieris Pharmaceuticals Inc
Progenra Inc
Promedior Inc
Prommune Inc
Prous Institute for Biomedical Research SA
Pulmatrix Inc
Pulmokine Inc
Qu Biologics Inc
Qurient Co Ltd
RAFT Pharmaceuticals
RAPT Therapeutics Inc
Re-Pharm Ltd
Regeneron Pharmaceuticals Inc
Reliance Life Sciences Pvt Ltd
Respiratorius AB
Revalesio Corp
ReveraGen BioPharma Inc
Ribomic Inc
S-TARget therapeutics GmbH
Saje Pharma LLC
Sam-A Pharm Co Ltd
Seelos Therapeutics, Inc.
Shanghai Kexin Biotech Co Ltd
Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co Ltd
Shouyao Holding Co Ltd
SolAeroMed Inc
sterna biologicals Gmbh & Co KG
Sun Pharma Advanced Research Company Ltd
Suzhou Connect Biopharmaceuticals Ltd
Swecure AB
Synermore Biologics Co Ltd
Taiho Pharmaceutical Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
TCF GmbH
Tetragenetics Inc
Teva Pharmaceutical Industries Ltd
TFF Pharmaceuticals Inc
The Geneva Biotech Center SA
Theravance Biopharma Inc
Torrent Pharmaceuticals Ltd
Translational Biosciences
Trio Medicines Ltd
Tunitas Therapeutics Inc
United BioPharma Inc
Vactech Oy
Vascular BioSciences
Vasomune Inc
Vectura Group Plc
Verona Pharma Plc
WhanIn Pharmaceutical Co Ltd
Xencor Inc
Yuhan Corp
Zai Lab Ltd


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[喘息治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆